Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 21, 2022 09:01 ET | Source: Research Dive

Hearing Amplifiers Market Estimated to Register $108.0 Billion and Grow at 5.9% CAGR by 2027 Post the Covid-19 Catastrophe | Declared by Research Dive

New York, USA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global hearing amplifiers market is estimated to register a revenue of $108.0 billion and...
November 22, 2021 06:42 ET | Source: The Insight Partners

$175.73Mn by 2028 Medical Audiometer Devices Market Size Lead by Hybrid Audiometers (4.4% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com

New York, Nov. 22, 2021 (GLOBE NEWSWIRE) -- According to our new research study on Medical Audiometer Devices Market Size, Share, Revenue, Forecast to 2028 - COVID-19 Impact and Global Analysis By...
May 04, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update

SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
April 07, 2021 22:02 ET | Source: Otonomy, Inc.

Otonomy Announces Pricing of $30.1 Million Public Offering

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
April 07, 2021 16:06 ET | Source: Otonomy, Inc.

Otonomy Announces Proposed Public Offering

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
March 25, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus

Phase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for primary efficacy endpointPatient enrollment criteria refined to enrich...
February 25, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
February 22, 2021 07:00 ET | Source: Otonomy, Inc.

Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
February 17, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing lossSupportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection...
February 11, 2021 16:17 ET | Source: Otonomy, Inc.

Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

OTIVIDEX® Phase 3 trial results in Ménière’s disease expected by end of FebruaryOTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in...

Next Page keyboard_arrow_right